Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Endo Elbows In On Valeant’s Pursuit Of Salix

Executive Summary

Bristol options rights to investigational prostate cancer immunotherapy, giving Bavarian Nordic additional funding to develop the candidate. Targacept finally calls it a day, in a reverse merger with Catalyst, while Arrowhead buys out the RNAi assets of Novartis.

Advertisement

Related Content

Santaris Acquisition By Roche May Help VCs Back New Biotechs In Europe
As Baxter Embarks On A New Course, It Bolsters Its Hemophilia Franchise
Endo’s Next Chapter Will Be Led By CEO De Silva
Targacept, AstraZeneca Face Another Failure With NNR Class
Second Time A Charm? Enzon Sells Biotech Business To Italian Pharma

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS056718

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel